``

WORK Medical Technology Group LTD (Nasdaq: WOK), a medical device supplier operating through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd., and its Chinese subsidiaries, announced today that it received a notification letter from Nasdaq on April 7, 2025. The letter stated that the company doesn’t meet the minimum bid price requirement for continued listing on the Nasdaq.

Nasdaq Listing Rule 5550(a)(2) mandates a minimum bid price of US$1.00 per share for listed securities. Rule 5810(c)(3)(A) stipulates that failure to meet this requirement for 30 consecutive business days constitutes a deficiency. The company’s Class A ordinary shares’ closing bid price remained below US$1.00 for 30 consecutive business days, from February 24, 2025 to April 4, 2025, resulting in non-compliance.

The notification does not immediately affect the company’s Nasdaq Capital Market listing. The company has been granted a 180-day period, until October 6, 2025, to regain compliance, as per Nasdaq Listing Rule 5810(c)(3)(A). To regain compliance, the company’s Class A ordinary shares must maintain a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. Failure to achieve compliance by October 6, 2025, may lead to an extension or potential delisting.

The notification letter does not impact the company’s business operations. The company plans to monitor the closing bid price of its Class A ordinary shares and may consider options such as a reverse share split to regain compliance with Nasdaq’s minimum bid price requirement.

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, via its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, supplies medical devices. It develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through its Chinese operating subsidiaries. The company’s product range includes 21 products, featuring customized and multifunctional masks and other medical consumables. These products are sold in 34 provincial-level administrative regions in China, with 15 products distributed in over 30 countries globally. The company holds several quality-related manufacturing certifications and has registered 17 products with the U.S. Food and Drug Administration for U.S. market entry. More details are available on the company’s website: .

Forward-Looking Statements

This press release includes forward-looking statements protected by the Private Securities Litigation Reform Act of 1995’s safe harbor provisions. These statements are identifiable by terms like “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and similar expressions. Any statements not based on historical facts within this release should be considered forward-looking.

These forward-looking statements reflect the company’s current expectations, estimates, and projections as of this release date and are subject to risks and uncertainties. These factors could cause actual results to significantly differ from those expressed or implied in these statements. While the company believes these expectations are reasonable, it cannot guarantee their accuracy. Investors are cautioned that actual results may vary materially from anticipated results and are encouraged to review other factors affecting the company’s future, as detailed in its annual report on Form 20-F and other SEC filings. The company disclaims any obligation to update these statements, except as legally required.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email: 

Ascent Investor Relations LLC
Tina Xiao
Phone: +1 646-932-7242
Email: